New research reveals that individuals who stop using popular GLP-1 drugs like Mounjaro or Wegovy may regain lost weight far faster than those who stop traditional diet and exercise regimens.
Published data in a major health publication shows that while obese people often shed a large proportion of their total mass while on the medication, the mass comes back at an average rate of nearly a kilo each month after stopping.
"People using these treatments need to be cognizant of the danger of fast weight regain when the treatment concludes," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery implies a return to original weight within about one and a half years.
Analyzing Approaches
The analysis, which reviewed dozens of studies involving thousands of patients, compared the outcomes of these new drugs with older methods.
Scientists note that individuals who shed pounds through lifestyle changes alone generally have a slower creep back—perhaps 100 grams monthly—post-intervention.
Understanding the Rapid Rebound
Doctors suggest the mechanism of the jabs is key to understanding the amplified rebound.
GLP-1 drugs copy a body's own chemical called GLP-1, which controls feelings of fullness.
"Long-term administration of GLP-1 concentrations several times higher than normal may cause the body to produce less of its endogenous hormone, and could lessen responsiveness to its effects," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this GLP-1 'fix' means appetite is unsuppressed, making overeating far more likely."
An Ongoing Disease?
Medical guidelines recommend the injections for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Professionals contend that, due to the significant potential of relapse, the therapy should be considered ongoing.
This opinion is echoed by drug manufacturers, who note that the results "emphasize the persistent nature of excess weight," akin to managing conditions like diabetes.
User Accounts
Individuals who have come off the jabs explain a intense resurgence of hunger.
"It was like a switch activating and I was suddenly extremely hungry," described an individual.
The struggle is exacerbated if patients have not established lasting dietary or behavioural changes during treatment.
Significant Interest
Survey data suggest that millions of people in the UK have used weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is higher among females than men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, clinicians stress that while these medications are powerful agents for shedding pounds, they are not a standalone fix and maintained weight loss relies on integrated behavioural support.
